Removal of Beta Blocker Drugs by Hemodialysis
Chronic Kidney Diseases
About this trial
This is an interventional basic science trial for Chronic Kidney Diseases focused on measuring hemodialysis, dialytic clearance, pharmacokinetics
Eligibility Criteria
Inclusion Criteria:
- at least 18 years of age, receiving hemodialysis three times per week for at least 90 days.
Exclusion Criteria:
- gastrointestinal or liver disease, body mass index greater than 40 kg/m2, contraindications for receiving a beta blocker (treatment with contraindicated medications, prior adverse reaction, severe reactive airway disease, hemodynamic instability during dialysis).
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Atenolol
Bisoprolol
Metoprolol
Carvedilol
Atenolol (50 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
Bisoprolol (5 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
Metoprolol (50 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
Carvedilol (6.25 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.